Diurnal Profile of the QTc Interval Following Moxifloxacin Administration.


Journal

Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372

Informations de publication

Date de publication:
01 2019
Historique:
received: 16 05 2018
accepted: 21 06 2018
pubmed: 25 7 2018
medline: 14 4 2020
entrez: 25 7 2018
Statut: ppublish

Résumé

Understanding the physiological fluctuations in the corrected QT (QTc) interval is important to accurately interpret the variations in drug-induced prolongation. The present study aimed to define the time course of the effect of moxifloxacin on the QT interval to understand the duration of the responses to moxifloxacin. This retrospective analysis was performed on data taken from a thorough QT 4-way crossover study with 40 subjects. Each period consisted of a baseline electrocardiogram (ECG) day (day -1) and a treatment day (day 1). On both days, ECGs were recorded simultaneously using 2 different systems operating in parallel: a bedside ECG and a continuous Holter recording. The subjects were randomized to 1 of 4 treatments: 5 mg and 40 mg of intravenous amisulpride, a single oral dose of moxifloxacin (400 mg), or placebo. Standardized meals, identical in all 4 periods, with similar nutritional value were served. Bedside ECG results confirmed that the moxifloxacin peak effect was delayed in the fed state and showed that the Fridericia corrected QT prolongation induced by moxifloxacin persisted until the end of the 24-hour measurement period. The use of continuous Holter monitoring provided further insight, as it revealed that the moxifloxacin effect on QTc was influenced by diurnal and nocturnal environmental factors, and hysteresis effects were noticeable. The findings suggested that moxifloxacin prolongs QTc beyond its elimination from the blood circulation. This is of relevance to current concentration-effect modeling approaches, which presume the absence of hysteresis effects.

Identifiants

pubmed: 30040135
doi: 10.1002/jcph.1283
doi:

Substances chimiques

Anti-Bacterial Agents 0
Moxifloxacin U188XYD42P

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-44

Informations de copyright

© 2018, The American College of Clinical Pharmacology.

Auteurs

Jörg Täubel (J)

Richmond Pharmacology Ltd., St George's University of London, London, UK.
Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, UK.

Georg Ferber (G)

Statistik Georg Ferber GmbH, Riehen, Switzerland.

Sara Fernandes (S)

Richmond Pharmacology Ltd., St George's University of London, London, UK.

A John Camm (AJ)

Cardiovascular and Cell Sciences Research Institute, St George's University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH